Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

investigation, the existence of this spliced variant in human may explain the evolution biology of SPARC and enhance the understanding of SPARC roles in carcinogenesis (Abstract #2778; Identification of a Splice Variant of Human SPARC mRNA with a Q3 Deletion).

The results of these pre-clinical studies support previous findings presented at the 2006 AACR conference, which demonstrated an increase in tumor response with nab-paclitaxel in SPARC-positive, head-and-neck cancer patients (83 percent) versus SPARC-negative, head-and-neck cancer patients (25 percent).

Abraxis continues to explore the role of nab-technology for targeting SPARC and other biological pathways, as well as for the development of new therapeutic candidates such as nab-docetaxel (ABI-008), the mTOR inhibitor nab-rapamycin (ABI-009), and the HSP90 inhibitor nab-17-AAG (ABI 010), among others.

About nab(TM) Technology Platform

Developed by Abraxis BioScience, nanoparticle albumin-bound (nab(TM)) tumor-targeting technology harnesses the unique natural properties of the human protein albumin, to transport and deliver therapeutic agents to the site of disease. The binding of albumin to the anticancer agent creates nanometer-sized particles, which are approximately 1/100th the size of a single red blood cell. These nab particles are readily incorporated into the body's own transport processes and are able to exploit the tumors' attraction to albumin, enabling the delivery of higher concentrations of the active drug to the target site. This may lead to an increase in the drug's antitumor effect and the potential for an effective response. In addition, nab technology offers the ability to improve a drug's solubility by avoiding the need for toxic chemicals, such as solvents, in the administration process, thus potentially improving safety through the elimination of solvent-related side effects.

Abraxis BioScience received approval from the U.S. Food and Drug Administration
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute ... a new therapeutic combination to combat resistant sarcomas. The ... could stabilize the growth of these tumors have been ... Cancer ., Sarcomas , Sarcomas are a rare ... subtypes. It can affect from children to older ages. ...
(Date:7/10/2014)... and cakes that are just as tempting as ... thanks to fresh insights into how proteins can ... , Funded by the Engineering and Physical ... University and the University of Edinburgh has produced ... and therefore closely mimic the behaviour of fats ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:New drug active against most aggressive type of lung cancer cells 2
... National Council on,Disability (NCD) today invited the Boston disability ... will take place at,the Hyatt Regency Boston, One Avenue ... 8:30 a.m. until 5:00 p.m.; Friday,November 30 from 8:30 ... a.m. until 11:15 a.m., Public comment sessions will ...
... IRVINE, Calif., Nov. 9 Masimo (Nasdaq: MASI ... Low Perfusion,pulse oximetry, announced today that the Pricing Committee ... rights plan. "This plan is designed to enhance ... acquire control of the company,that do not offer an ...
... N.C. and ALPHARETTA, Ga., Nov. 9 ... diagnostic imaging,services, officially joined Novant Health today ... acquisition. MedQuest will operate as a,wholly-owned subsidiary ... not-for-profit integrated healthcare system serving,North and South ...
... 9, 2007) A gender difference exists among surgeons ... the factors that may influence their career choice, according ... November issue of the Journal of the American College ... higher percentage of women than men were influenced by ...
... effective in easing pain, study finds , FRIDAY, Nov. 9 ... reduce disease activity and pain in patients with chronic active ... of 10 patients, average age 62, who had gout for ... by Dr. Robert Terkeltaub of the VA Medical Center and ...
... 8th annual gala and auction November 16 to benefit Girls ... to kayak, golf, run, bike,dine, relax, shop, travel and more ... Go Girl Gala, taking place Friday November 16 at the,Chicago ... and fitness enthusiasts, features live music from the Underwater,People, cocktails, ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Novant Health Completes Purchase of MedQuest 2Health News:Novant Health Completes Purchase of MedQuest 3Health News:Survey shows gender differences are factor when surgeons in training choose a subspecialty 2Health News:Chicago's Premier Sports and Fitness Auction is Back! 2
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
... weighing mechanism for speed, stability and ... analog display modes, multiple units of ... functions, auto print, and GLP/GMP/ISO output ... built-in clock. Built-in, motor-driven internal ...
... - Battery Powered (6 size AA required). ... (g, ct, oz, ozt, GN, dwt, mom, ... and Percent Measure functions, Auto Print. Optional ... AC adapter may be ordered for AC ...
Medicine Products: